EUCTR2014-001325-33-DE进行中（未招募）1 期
Prospective donor-specific Cellular alloresponse assessment for Immunosuppression Minimization in de novo renal transplantation
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 669
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1)Men and women, age =18 years.
- •2)Subject must be a recipient of a first renal transplant from a deceased or living donor.
- •3)Subject must have a current documented PRA <20% and no detectable anti-class I and II HLA antibodies by solid phase assay (Luminex®).
- •4)Subject is willing to provide signed written informed consent.
- •5)Women of Childbearing Potential (WOCBP) must be using two highly effective method of contraception (Pearl-Index < 1) simultaneously to avoid pregnancy throughout the study and for 6 weeks after last MMF treatment in such a manner that the risk of pregnancy is minimized. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea = 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level > 35 mIU/mL]. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of clinical trial.
- •6)Sexually active (including vasectomised) men taking mycophenolate are willing to use condoms for sex during MMF treatment and for 90 days thereafter; partners of childbearing potential have to use highly effective contraception for the same period.
- •7)Subjects are willing not to donate blood during and for 6 weeks after MMF treatment, and men could not donate sperm during MMF treatment and for 90 days after stopping MMF treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 447
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 222
排除标准
- •1)Subjects undergoing renal transplant with a current documented PRA >20% and/or detectable anti-class I and II HLA antibodies by solid phase assay (Luminex®).
- •2)CDC positive cross match.
- •3)Subjects receiving an allograft from a donor older than 65 years with elevated creatinine levels and/or treated diabetes.
- •4)Cold ischemia time (CIT) higher than 24h.
- •5)Subjects with a prior solid organ transplant (SOT), including renal re-transplantation, or receiving a concurrent SOT.
- •6)Patients previously treated with daclizumab or basiliximab.
- •7)Subjects with underlying renal disease of:
- •a.Primary focal segmental glomerulosclerosis.
- •b.Type I or II membranoproliferative glomerulonephritis
- •c.Atypical Haemolytic uremic syndrome (HUS) / thrombotic thrombocytopenic purpura syndrome.
- •8)Subject with Hepatitis B chronic infection and/or active infection by Hepatitis C virus (positive PCR result) at the moment of transplant.
- •9)Subjects with known human immunodeficiency virus (HIV) infection.
- •10)Patients with active systemic infection that requires the continued use of antibiotics.
- •11)Patients with neoplasia except localized skin cancer receiving appropriate treatment.
- •12)Patients with severe anemia (hemoglobin < 6g/dl), leucopenia (WBC <2500/mm3), thrombocytopenia (platelets <80.000/mm3).
- •13)Hemodynamically instable patients even if their hemoglobin level counts > 6 g/dl.
- •14)Patients with intestinal pathology or severe diarrhoea that can hinder absorption according to medical criteria.
- •15)Subjects with a known hyper sensibility to any of the drugs used in this protocol.
- •16)Subjects who have used any investigational drug within 30 days prior to enrolment in this clinical trial.
- •17)WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period, women who are pregnant or breastfeeding or women with a positive pregnancy test on enrolment.
- •18)Subjects who are legally detained in an official institution
研究者
相似试验
进行中（未招募）
不适用
Individual assessment for Immunosuppression Minimization in transplanted patients.kidney transplant patientsEUCTR2014-001325-33-NLCharité - Universitätsmedizin Berlin669
进行中（未招募）
1 期
Individual assessment for Immunosuppression Minimization in transplanted patients.kidney transplant patientsEUCTR2014-001325-33-CZCharité - Universitätsmedizin Berlin669
进行中（未招募）
1 期
Individual assessment for Immunosuppression Minimization in transplanted patients.kidney transplant patientsEUCTR2014-001325-33-ESCharité - Universitätsmedizin Berlin167
招募中
2 期
Prospective donor-specific Cellular alloresponse assessment for Immunosuppression Minimization in de novo renal transplantatioimmuneresponserenal transplantation10038430NL-OMON45147Charite Universiteitskliniek Berlijn200
进行中（未招募）
不适用
INDUCTION OF DONOR-SPECIFIC TOLERANCE IN PATIENTS WITH LIVER TRANSPLANTATION WITH RECIPIENT PRE-TREATMENT WITH THYMOGLOBULINE AND MINIMAL POST-TRANSPLANT IMMUNOSUPPRESSION. - NDAdult recipients of first liver transplantationMedDRA version: 9.1Level: LLTClassification code 10024715Term: Liver transplant rejectionEUCTR2009-010640-34-ITAZIENDA OSPEDALIERA POLICLINICO DI MODENA